CalciMedica (CALC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $220M

Market Cap: $9.8MFounded: 2006HQ: La Jolla, United States

Sector Ranking#344 in Small Molecule Drugs #74 in Immunotherapy / Immuno-Oncology

Overview

CalciMedica's mission is to develop first-in-class CRAC channel inhibitors for acute inflammatory and immunologic diseases with high mortality and no approved therapies. Its primary achievement is advancing its lead candidate, Auxora (zegocractin), into Phase 2 development for acute pancreatitis and acute kidney injury, though a recent trial in AKI was discontinued. The company's strategy is to leverage its proprietary CRAC channel platform to modulate the immune response and protect against tissue cell injury, targeting critical care markets with substantial unmet need.

Acute Inflammatory DiseasesImmunology

Technology Platform

Proprietary platform for developing small molecule inhibitors of Calcium Release-Activated Calcium (CRAC) channels, targeting the Orai1 subunit to modulate immune response and protect tissue cells from injury.

Funding History

5

Total raised:$220M

Series C$42MSofinnova InvestmentsJun 15, 2023

Series C$62MSofinnova PartnersJul 15, 2022

Series B$47MSofinnova InvestmentsJan 15, 2022

Series B$42MNovo HoldingsDec 15, 2020

Opportunities

Auxora targets acute pancreatitis, a condition affecting ~300,000 U.S.

hospitalizations annually with no approved disease-modifying therapy, representing a multi-billion dollar market opportunity.

Success would validate the novel CRAC channel platform, potentially opening avenues for development in other acute and chronic inflammatory diseases.

Risk Factors

Extreme financial risk with a ~$10M valuation and limited cash, threatening the company's ability to fund its next clinical trial.

High clinical risk as the company's future depends entirely on the success of a single Phase 2b trial in acute pancreatitis following the recent discontinuation of its AKI program.

Competitive Landscape

CalciMedica is a first-mover in developing Orai1/CRAC channel inhibitors for acute care, facing no direct mechanism-of-action competitors. Its primary competition is the entrenched standard of supportive care in acute pancreatitis and the high historical failure rate of drug development in this indication.